标题
Have we overestimated the benefit of human(ized) antibodies?
作者
关键词
-
出版物
mAbs
Volume 2, Issue 6, Pages 682-694
出版商
Informa UK Limited
发表日期
2010-12-01
DOI
10.4161/mabs.2.6.13601
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
- (2014) David J. Shealy et al. mAbs
- Natalizumab (Tysabri)
- (2010) D.T. Selewski et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma
- (2010) Gustavo J. Rodrigo et al. CHEST
- U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
- (2010) S. J. Lemery et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
- (2010) B. Kuenen et al. CLINICAL CANCER RESEARCH
- Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
- (2010) Gary R. Lichtenstein et al. Clinical Gastroenterology and Hepatology
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
- (2010) Xunrong Luo et al. IMMUNITY
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
- (2010) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
- (2010) J. Somerfield et al. JOURNAL OF IMMUNOLOGY
- Ustekinumab
- (2010) Oya Cingoz mAbs
- Structural and functional characterization of the trifunctional antibody catumaxomab
- (2010) Dirk Chelius et al. mAbs
- Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
- (2010) Frank R. Brennan et al. mAbs
- Canakinumab
- (2010) Eugen Dhimolea mAbs
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis
- (2010) Mona Gandhi et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Eculizumab
- (2009) Eline A. Dubois et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
- (2009) Kevan C. Herold et al. CLINICAL IMMUNOLOGY
- Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
- (2009) PY Muller et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
- (2009) Patrick Y Muller et al. CURRENT OPINION IN BIOTECHNOLOGY
- Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study
- (2009) Nasia Safdar et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Current situation of zalutumumab
- (2009) Fernando Rivera et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Certolizumab pegol for the treatment of Crohn’s disease
- (2009) Danial E Baker Expert Review of Clinical Immunology
- Veto on vedolizumab (MLN0002) for Crohnʼs disease
- (2009) Daniel C. Baumgart INFLAMMATORY BOWEL DISEASES
- Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis†
- (2009) Daniel C. Baumgart et al. INFLAMMATORY BOWEL DISEASES
- Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer
- (2009) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Michael Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)
- (2009) Martin Sebastian et al. JOURNAL OF IMMUNOTHERAPY
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
- (2009) Daniel D. Karp et al. Journal of Thoracic Oncology
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
- (2009) David Olmos et al. LANCET ONCOLOGY
- Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
- (2009) Helen J. Lachmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raxibacumab for the Treatment of Inhalational Anthrax
- (2009) Thi-Sau Migone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
- (2008) Jonathan Kay et al. ARTHRITIS AND RHEUMATISM
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome
- (2008) Dominik Sebastian Mestel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases
- (2008) Changhai Ding EXPERT OPINION ON BIOLOGICAL THERAPY
- Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
- (2008) Luis H Camacho EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
- (2008) Angèle L.M. Oei et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
- (2008) Georgiana K. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
- (2008) Richard Furie et al. ARTHRITIS RESEARCH & THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started